{
    "id": 25629,
    "fullName": "MET D1228H",
    "impact": "missense",
    "proteinEffect": "gain of function",
    "geneVariantDescriptions": [
        {
            "description": "MET D1228H (corresponding to D1246H in isoform 2) lies within the protein kinase domain of the Met protein (UniProt.org). D1228H results in constitutive Met autophosphorylation and increased substrate phosphorylation, is transforming in cell culture (PMID: 9826708), and has been demonstrated to confer Met inhibitor resistance in the context of a co-occurring Met exon 14 skipping mutation (PMID: 31279006).",
            "references": [
                {
                    "id": 295,
                    "pubMedId": null,
                    "title": null,
                    "url": "https://www.uniprot.org"
                },
                {
                    "id": 6847,
                    "pubMedId": 9826708,
                    "title": "Uncoupling signal transducers from oncogenic MET mutants abrogates cell transformation and inhibits invasive growth.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/9826708"
                },
                {
                    "id": 16006,
                    "pubMedId": 31279006,
                    "title": "Sensitivity and Resistance of MET Exon 14 Mutations in Lung Cancer to Eight MET Tyrosine Kinase Inhibitors In\u00a0Vitro.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31279006"
                }
            ]
        }
    ],
    "type": null,
    "gene": {
        "id": 4233,
        "geneSymbol": "MET",
        "terms": [
            "MET",
            "AUTS9",
            "c-Met",
            "DFNB97",
            "HGFR",
            "RCCP2"
        ]
    },
    "variant": "D1228H",
    "createDate": "10/25/2016",
    "updateDate": "10/25/2019",
    "referenceTranscriptCoordinates": {
        "id": 144655,
        "transcript": "NM_000245",
        "gDna": "chr7:g.116783353G>C",
        "cDna": "c.3682G>C",
        "protein": "p.D1228H",
        "sourceDb": "RefSeq",
        "refGenomeBuild": "GRCh38/hg38"
    },
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 10071,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Altiratinib (DCC-2701) inhibited activity of MET D1228H in an in vitro kinase assay (PMID: 26285778).",
            "molecularProfile": {
                "id": 26646,
                "profileName": "MET D1228H"
            },
            "therapy": {
                "id": 1656,
                "therapyName": "Altiratinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 7263,
                    "pubMedId": 26285778,
                    "title": "Altiratinib Inhibits Tumor Growth, Invasion, Angiogenesis, and Microenvironment-Mediated Drug Resistance via Balanced Inhibition of MET, TIE2, and VEGFR2.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26285778"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 12554,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial, a patient with papillary renal cell carcinoma harboring MET D1228H demonstrated a partial response with a duration of 21.8 months when treated with Xalkori (crizotinib) (PMID: 29149761; NCT01524926).",
            "molecularProfile": {
                "id": 26646,
                "profileName": "MET D1228H"
            },
            "therapy": {
                "id": 706,
                "therapyName": "Crizotinib",
                "synonyms": null
            },
            "indication": {
                "id": 4465,
                "name": "papillary renal cell carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 10419,
                    "pubMedId": 29149761,
                    "title": "Crizotinib achieves long-lasting disease control in advanced papillary renal-cell carcinoma type 1 patients with MET mutations or amplification. EORTC 90101 CREATE trial.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29149761"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 14449,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, a patient with lung adenocarcinoma harboring EGFR L858R and EGFR T790M, MET amplification and MET D1228H, MET D1228N, MET Y1230H, and MET D1231Y demonstrated initial symptomatic improvement, decreased pleural effusion, and lung nodule shrinkage following treatment with the combination of Cometriq (Cabometyx, cabozantinib) and Tagrisso (osimertinib) (PMID: 29128427).",
            "molecularProfile": {
                "id": 30018,
                "profileName": "EGFR T790M EGFR L858R MET D1228H MET D1228N MET Y1230H MET D1231Y MET amp"
            },
            "therapy": {
                "id": 7090,
                "therapyName": "Cabozantinib + Osimertinib",
                "synonyms": null
            },
            "indication": {
                "id": 3910,
                "name": "lung adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "unknown",
            "references": [
                {
                    "id": 11634,
                    "pubMedId": 29128427,
                    "title": "Osimertinib and Cabozantinib Combinatorial Therapy in an EGFR-Mutant Lung Adenocarcinoma Patient with Multiple MET Secondary-Site Mutations after Resistance to Crizotinib.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29128427"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 14448,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, a patient with lung adenocarcinoma harboring EGFR L858R and EGFR T790M and MET amplification demonstrated progressive disease after 3 months of treatment with the combination of Tagrisso (osimertinib) and Xalkori (crizotinib) and was found to have acquired 4 MET mutations: MET D1228H, MET D1228N, MET Y1230H, and MET D1231Y (PMID: 29128427).",
            "molecularProfile": {
                "id": 30018,
                "profileName": "EGFR T790M EGFR L858R MET D1228H MET D1228N MET Y1230H MET D1231Y MET amp"
            },
            "therapy": {
                "id": 4958,
                "therapyName": "Crizotinib + Osimertinib",
                "synonyms": null
            },
            "indication": {
                "id": 3910,
                "name": "lung adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 11634,
                    "pubMedId": 29128427,
                    "title": "Osimertinib and Cabozantinib Combinatorial Therapy in an EGFR-Mutant Lung Adenocarcinoma Patient with Multiple MET Secondary-Site Mutations after Resistance to Crizotinib.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29128427"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 18211,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, expression of MET D1228H secondary to a MET exon 14 skipping mutation in transformed cells conferred resistant to Savolitinib (AZD6094) in culture (PMID: 31279006).",
            "molecularProfile": {
                "id": 33020,
                "profileName": "MET del exon14 MET D1228H"
            },
            "therapy": {
                "id": 2161,
                "therapyName": "Savolitinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 16006,
                    "pubMedId": 31279006,
                    "title": "Sensitivity and Resistance of MET Exon 14 Mutations in Lung Cancer to Eight MET Tyrosine Kinase Inhibitors In\u00a0Vitro.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31279006"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 18212,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, expression of MET D1228H secondary to a MET exon 14 skipping mutation in transformed cells resulted in decreased response to Cometriq (Cabometyx, cabozantinib) in culture (PMID: 31279006).",
            "molecularProfile": {
                "id": 33020,
                "profileName": "MET del exon14 MET D1228H"
            },
            "therapy": {
                "id": 998,
                "therapyName": "Cabozantinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 16006,
                    "pubMedId": 31279006,
                    "title": "Sensitivity and Resistance of MET Exon 14 Mutations in Lung Cancer to Eight MET Tyrosine Kinase Inhibitors In\u00a0Vitro.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31279006"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 18210,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, expression of MET D1228H secondary to a MET exon 14 skipping mutation in transformed cells conferred resistant to Tepotinib (MSC2156119J) in culture (PMID: 31279006).",
            "molecularProfile": {
                "id": 33020,
                "profileName": "MET del exon14 MET D1228H"
            },
            "therapy": {
                "id": 1398,
                "therapyName": "Tepotinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 16006,
                    "pubMedId": 31279006,
                    "title": "Sensitivity and Resistance of MET Exon 14 Mutations in Lung Cancer to Eight MET Tyrosine Kinase Inhibitors In\u00a0Vitro.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31279006"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 18213,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Merestinib (LY2801653) inhibited growth of transformed cells expressing MET D1228H secondary to a MET exon 14 skipping mutation in culture (PMID: 31279006).",
            "molecularProfile": {
                "id": 33020,
                "profileName": "MET del exon14 MET D1228H"
            },
            "therapy": {
                "id": 1030,
                "therapyName": "Merestinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 16006,
                    "pubMedId": 31279006,
                    "title": "Sensitivity and Resistance of MET Exon 14 Mutations in Lung Cancer to Eight MET Tyrosine Kinase Inhibitors In\u00a0Vitro.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31279006"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 18208,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, expression of MET D1228H secondary to a MET exon 14 skipping mutation in transformed cells conferred resistant to Xalkori (crizotinib) in culture (PMID: 31279006).",
            "molecularProfile": {
                "id": 33020,
                "profileName": "MET del exon14 MET D1228H"
            },
            "therapy": {
                "id": 706,
                "therapyName": "Crizotinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 16006,
                    "pubMedId": 31279006,
                    "title": "Sensitivity and Resistance of MET Exon 14 Mutations in Lung Cancer to Eight MET Tyrosine Kinase Inhibitors In\u00a0Vitro.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31279006"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 18209,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, expression of MET D1228H secondary to a MET exon 14 skipping mutation in transformed cells conferred resistant to Capmatinib (INC280) in culture (PMID: 31279006).",
            "molecularProfile": {
                "id": 33020,
                "profileName": "MET del exon14 MET D1228H"
            },
            "therapy": {
                "id": 1065,
                "therapyName": "Capmatinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 16006,
                    "pubMedId": 31279006,
                    "title": "Sensitivity and Resistance of MET Exon 14 Mutations in Lung Cancer to Eight MET Tyrosine Kinase Inhibitors In\u00a0Vitro.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31279006"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 18214,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Glesatinib (MGCD265) inhibited growth of transformed cells expressing MET D1228H secondary to a MET exon 14 skipping mutation in culture (PMID: 31279006).",
            "molecularProfile": {
                "id": 33020,
                "profileName": "MET del exon14 MET D1228H"
            },
            "therapy": {
                "id": 809,
                "therapyName": "Glesatinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 16006,
                    "pubMedId": 31279006,
                    "title": "Sensitivity and Resistance of MET Exon 14 Mutations in Lung Cancer to Eight MET Tyrosine Kinase Inhibitors In\u00a0Vitro.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31279006"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19109,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, a patient with cholangiocarcinoma harboring PLEKHA6-NTRK1 and MET amplification initially demonstrated sensitivity to the combination therapy of Xalkori (crizotinib) and LOXO-195, but progressed after 4.5 months and was found to have acquired 13 new MET missense mutations, MET D1228H, MET D1228N, MET Y1230H, MET Y1230S, MET Y1230N, MET D1228Y, MET G1090S, MET G1090A, MET R1227K, MET D1213H, MET 1195V, MET Y1230C, and MET V1092I (PMID: 31406350).",
            "molecularProfile": {
                "id": 33935,
                "profileName": "PLEKHA6 - NTRK1 MET G1090A MET G1090S MET V1092I MET L1195V MET D1213H MET R1227K MET D1228H MET D1228N MET D1228Y MET Y1230C MET Y1230H MET Y1230N MET Y1230S MET amp"
            },
            "therapy": {
                "id": 8913,
                "therapyName": "Crizotinib + LOXO-195",
                "synonyms": null
            },
            "indication": {
                "id": 4947,
                "name": "cholangiocarcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 16397,
                    "pubMedId": 31406350,
                    "title": "Resistance to TRK inhibition mediated by convergent MAPK pathway activation.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31406350"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 20334,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical study, a patient with non-small cell lung cancer harboring MET D1010H responded to Xalkori (crizotinib) for 10.8 months, but then progressed, and was found to have acquired MET D1228H (PMID: 32034073).",
            "molecularProfile": {
                "id": 35121,
                "profileName": "MET D1010H MET D1228H"
            },
            "therapy": {
                "id": 706,
                "therapyName": "Crizotinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 17807,
                    "pubMedId": 32034073,
                    "title": "Molecular mechanisms of acquired resistance to MET tyrosine kinase inhibitors in patients with MET exon 14 mutant NSCLC.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/32034073"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 26646,
            "profileName": "MET D1228H",
            "profileTreatmentApproaches": [
                {
                    "id": 10734,
                    "name": "MET Inhibitor",
                    "profileName": "MET D1228H"
                }
            ]
        },
        {
            "id": 30018,
            "profileName": "EGFR T790M EGFR L858R MET D1228H MET D1228N MET Y1230H MET D1231Y MET amp",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 33020,
            "profileName": "MET del exon14 MET D1228H",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 33935,
            "profileName": "PLEKHA6 - NTRK1 MET G1090A MET G1090S MET V1092I MET L1195V MET D1213H MET R1227K MET D1228H MET D1228N MET D1228Y MET Y1230C MET Y1230H MET Y1230N MET Y1230S MET amp",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 35121,
            "profileName": "MET D1010H MET D1228H",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        {
            "id": 144655,
            "transcript": "NM_000245",
            "gDna": "chr7:g.116783353G>C",
            "cDna": "c.3682G>C",
            "protein": "p.D1228H",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        }
    ]
}